Table 1.
Baseline demographics for each medication group
| Variable | Acamprosatea (n = 72) | Disulfiram (n = 143) | Naltrexone (n = 551) | Extended-release naltrexone (n = 41) |
| Age at trial onset, years | 52.8 | 49.7 | 51.4 | 52.1 |
| % Male | 91.7 | 90.9 | 91.6 | 95.1 |
| % White | 77.8 | 61.0 | 52.3 | 65.0 |
| % African American | 20.8 | 38.3 | 47.1 | 35.0 |
a
Indicates significant difference in age between the acamprosate group compared with the disulfiram group (p = .02) and in race between acamprosate and both the disulfiram and naltrexone groups (p ≤ .01).